Kathy Lee-Sepsick is the founder of Femasys, established in February 2004. She brings nearly three decades of leadership in the medical technologies industry, with a proven track record in scaling emerging companies and operating divisions. Ms. Lee-Sepsick holds over 200 global patents for Femasys’ products and candidates. Previously, she held strategic, operational, and executive roles across various company life cycles, including at Novoste Corporation (intravascular therapy) and SaluMedica (biomaterials for artificial cartilage). Early in her career, she managed product strategy at Terumo Medical Corporation, collaborating closely with Boston Scientific. Ms. Lee-Sepsick earned a BS in Biochemistry and an MBA from Rutgers University.